In order to enable an iCal export link, your account needs to have an API key created. This key enables other applications to access data from within Indico even when you are neither using nor logged into the Indico system yourself with the link provided. Once created, you can manage your key at any time by going to 'My Profile' and looking under the tab entitled 'HTTP API'. Further information about HTTP API keys can be found in the Indico documentation.
Additionally to having an API key associated with your account, exporting private event information requires the usage of a persistent signature. This enables API URLs which do not expire after a few minutes so while the setting is active, anyone in possession of the link provided can access the information. Due to this, it is extremely important that you keep these links private and for your use only. If you think someone else may have acquired access to a link using this key in the future, you must immediately create a new key pair on the 'My Profile' page under the 'HTTP API' and update the iCalendar links afterwards.
Permanent link for public information only:
Permanent link for all public and protected information:
Pharmaceutical development of the ISOL technique for the production of radionuclides and their applications in targeted radionuclide therapy
M.B. Ceolin meeting room (INFN-LNL)
M.B. Ceolin meeting room
Radiopharmaceuticals are the fundamental tool for nuclear medicine procedures, enabling imaging and therapy of cancer after administration of a radioligand. The discovery and production of new radionuclides on one side and the optimization of ligands on the other are central parts of the research in the radiopharmaceutical field. The ISOLPHARM projects aims at the production of innovative radionuclides ideal for targeting malignant tissues because, thanks to mass separation, they are extremely pure, i.e. carrier-free. Thanks to the SPES UCx target and to innovative not-fissile targets, several radionuclides are under investigation for production at LNL-INFN with the ISOL technique, for example 111Ag and 64/67Cu. In this seminar a strategy for ligands optimization will also be discussed, regarding in particular the introduction of a serum protein-binding domain in the chemical structure of the radioconjugates to improve their pharmacokinetic properties. The last part of the work presented was developed at the Center for Radiopharmaceutical Sciences at Paul Scherrer Institute (CH).